Description: A Phase 1, First-in-Human, Dose Escalation and Expansion Study of MGD024, a CD123 X CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies
Mechanism of Action: DART- CD123/CD3 biospecific
Target Patient Population: Select hematologic malignancies known to overexpress CD123 including AML, MDS, Hodgkins, CML, B-ALL, Hairy Cell Leukemia, Advanced Systemic Mastocytosis and Blastic Plasmacytoid Dendridic Cell Neoplasm
Study Design: Drug is given IV every 2 weeks. Patient is admitted for observation for 48-72 hours depending on dosing post 1st treatment.